The advanced aseptic processing of ADVASEPT® technology can reduce the risk associated with aseptic filling of biologics and drastically reduce the potential of foreign particulates. The technology automates the container formation, filling and sealing of the vial to create a glass free injectables platform. For over 20 years, BFS has been used for a commercial biologic drug product and Catalent has recently completed a direct comparison of a model mAb filled in glass vials and ADVASEPT ® Vials. To learn more about the technology: Click to download two year Biologics Case Study.
